Estrella Immunopharma (Estrella Immunopharma) Other Long-Term Liabilities : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Other Long-Term Liabilities?

Estrella Immunopharma's other long-term liabilities for the quarter that ended in Mar. 2024 was $0.00 Mil.

Estrella Immunopharma Other Long-Term Liabilities Historical Data

The historical data trend for Estrella Immunopharma's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Other Long-Term Liabilities Chart

Estrella Immunopharma Annual Data

Trend

Jun21

Other Long-Term Liabilities

Estrella Immunopharma Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Other Long-Term Liabilities	Get a 7-Day Free Trial					-	-	-	-	-

Estrella Immunopharma Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Estrella Immunopharma Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma (Estrella Immunopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLAW) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

ESLA:USA

Address

5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608

Website

https://www.estrellabio.com

Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines